Ask about this productRelated genes to: SEMA4A antibody
- Gene:
- SEMA4A NIH gene
- Name:
- semaphorin 4A
- Previous symbol:
- SEMAB
- Synonyms:
- SemB, FLJ12287, CORD10
- Chromosome:
- 1q22
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-22
- Date modifiied:
- 2016-01-14
Related products to: SEMA4A antibody
Related articles to: SEMA4A antibody
- - Source: PubMed
Publication date: 2026/04/09
Li XinyuYao BinyuSun MeilingLi WangshiLv XingzhiLuo KeyangWu YueXiu RuolinMa YuzhuLiu FukaiZhao YanhongFan ShengjinTang LinqingFan Huitao - Psoriasis is an autoimmune systemic disease of not entirely understood pathogenesis. It remains a significant therapeutic challenge and, due to its various comorbidities, has a remarkable detrimental effect on patients' wellbeing. Semaphorins (Sema) are a group of transmembrane, cell surface-attached and secretory proteins that might play an important role in psoriasis due to their presence on keratinocytes and the ability to stimulate the proinflammatory cytokine production. - Source: PubMed
Publication date: 2026/03/12
Baran AnnaStepaniuk AnnaHermanowicz Justyna MagdalenaSieklucka BeataPawlak KrystynaPawlak DariuszFlisiak Iwona - Lung cancer is a highly heterogeneous disease, and the tumor microenvironment (TME) characteristics are closely related to disease progression and treatment outcomes. We elucidated the cell type-specific transcriptome landscape of cancer cells and the effect of the TME on lung adenocarcinoma (LUAD). - Source: PubMed
Publication date: 2025/12/03
Cao ZimengBai XuefengLi JingCai JinruCao GangXiao YuncaiZhou Wei - Brucellosis, a zoonotic disease caused by infection, poses a major threat to both global health and livestock productivity. Although reproductive impairment is well established, the molecular mechanisms driving testicular immunopathology remain poorly understood. In this study, single-cell RNA sequencing was used to delineate transcriptional changes in goat testicular tissues under physiological and -infected conditions, revealing dynamic immunological remodeling of the testicular microenvironment. Infection induced marked shifts in T cell and macrophage phenotypes, with T cells exhibiting pronounced hyperactivation linked to CD45-mediated signaling cascades. Thioredoxin-interacting protein ( ), a gene strongly up-regulated in response to infection, emerged as a potential immunotherapeutic target. Intercellular communication networks were significantly disrupted in infected testes, with CD39- and JAM-dependent signaling pathways implicated in the erosion of immune privilege. Regulon analysis further identified GATA3, IRF5, SEMA4A, and HCLS1 as transcriptional regulators associated with T cells and macrophages in infected testes. These findings provide novel insights into the molecular mechanisms driving testicular immunopathology during infection and highlight candidate targets for immunomodulatory intervention in disease control and livestock reproductive health. - Source: PubMed
Chen Wen-BoWang Cong-LiangWan Shi-ChengLuo XuanYang Dong-HuiZhang Meng-FeiWu Wen-PingLi NaHan BinZhu Hai-JingYu Hai-ShengHua Jin-Lian - Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) for multiple myeloma (MM) is effective, but relapses associated with low-to-negative BCMA expression are common, indicating the need for additional targets. We quantitatively profile antigen density in a cohort of patients relapsed after BCMA CAR T therapy, showing high number of SEMA4A molecules/cell where BCMA density is low. SEMA4A deletion limits MM cell growth, migration, tissue infiltration, and osteoclast formation, while extending mouse survival. We generate monoclonal antibodies targeting SEMA4A-extracellular domain for CAR construction, screen engineered T cells for expansion, cytokine release, and cytotoxicity against MM cells. Lead constructs lack reactivity against normal non-hematopoietic tissues. SEMA4A CAR T cells show superior efficacy than BCMA CAR T cells eliminating patient-derived BCMA tumors and MM cells progressing under suboptimal doses of BCMA CAR T cells. This study prepares for a phase 1 clinical trial with SEMA4A-directed CAR T cells for MM. - Source: PubMed
Publication date: 2025/10/09
Di Meo FrancescoAlbano FrancescaCesarano AnnamariaWang YunfeiKale BrandonShain KennethSilva AriostoKurihara NoriyoshiTenshin HirofumiJellyman DavidSong XiaofeiGhaffari SasanMesa HectorCreelan BenFreeman CiaraZhao XiaohongMeads Mark BRodriguez Paulo CMarino SilviaLocke FrederickHwu PatrickRoodman DavidMansilla-Soto JorgePerna Fabiana